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Corneal transplantation by full-thickness
penetrating keratoplasty with human
donor tissue is a widely accepted treat-
ment for damaged or diseased corneas.
Although corneal transplantation has a
high success rate, a shortage of high-
quality donor tissue is a considerable
limitation. Therefore, bioengineered cor-
neas could be an effective solution for
this limitation, and a decellularized
extracellular matrix comprises a promising scaffold for their fabrication. In this
study, three-dimensional bioprinted decellularized collagen sheets were implanted
into the stromal layer of the cornea of five rabbits. We performed in vivo noninva-
sive monitoring of the rabbit corneas using swept-source optical coherence tomogra-
phy (OCT) after implanting the collagen sheets. Anterior segment OCT images and
averaged amplitude-scans were acquired biweekly to monitor corneal thickness after
implantation for 1 month. The averaged cornea thickness in the control images was
430.3 ± 5.9 μm, while the averaged thickness after corneal implantation was
598.5 ± 11.8 μm and 564.5 ± 12.5 μm at 2 and 4 weeks, respectively. The corneal
thickness reduction of 34 μm confirmed the biocompatibility through the image anal-
ysis of the depth-intensity profile base. Moreover, hematoxylin and eosin staining
supported the biocompatibility evaluation of the bioprinted decellularized collagen
sheet implantation. Hence, the developed bioprinted decellularized collagen sheets
could become an alternative solution to human corneal donor tissue, and the pro-
posed image analysis procedure could be beneficial to confirm the success of the
surgery.
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1 | INTRODUCTION
The cornea is a transparent nonvascular tissue located in the
outermost layer of the eye and plays a significant role in the
visual function by refracting and transmitting light [1]. Irre-
versible corneal damage can lead to vision loss and corneal
transplantation is the only accepted treatment to avoid cor-
neal blindness [2]. Although corneal transplantation has
been performed for over 100 years, there are some critical
problems to this procedure, including graft rejection, graft
failure and a lack of donors [3–5]. To solve these problems,
the implantation of an artificial cornea, known as a
keratoprosthesis, has been introduced and is widely per-
formed [6–11]. A keratoprosthesis is considered as an alter-
native treatment when corneal transplantation has failed or
in cases of severe limbal epithelial deficiency with dissipated
epithelial regenerative capacity after conditions such as
chemical burns, Stevens-Johnson syndrome and ocular cica-
tricial pemphigoid. However, it is a prosthetic device that is
made of synthetic material and causes some serious compli-
cations, including persistent epithelial defects, prosthetic
extrusion, retroprosthetic membrane formation and
endophthalmitis. Thus, from a clinical perspective, bio-
engineered corneal substitutes using biocompatible materials
are needed to overcome the shortcomings of corneal
allografts.
Decellularized extracellular matrix (ECM) scaffolds
derived from tissues have been effectively used in human
clinical applications. The composition of the ECM varies
according to the type of tissue as it exhibits tissue-specific
directed differentiation and the stem cells mature into a spe-
cific lineage. Therefore, the cells in the engineered tissue are
more likely to mature if they are given an ECM environment
that is similar to the original tissue and organ (eg, heart [12],
skeletal muscle [13], dermis [14], lung [15] and liver [16]).
In addition, three-dimensional (3D) bioprinting is a
promising technology for building patient-specific complex
living structures in 3D via the direct deposition of biomate-
rials, biomolecules and cells [17]. Likewise, 3D bioprinting
using an ECM with decellularized corneal tissue offers a
new strategy for the fabrication of bioengineered cornea and
in particular, could be applied in the fabrication of patient-
specific corneas that have different curvatures or thick-
nesses. Thus, the implantation of patient-specific 3D
bioprinted corneas made of ECM components could replace
existing treatments. Fabricated bioengineered corneal substi-
tutes are generally evaluated using histologic examinations
in experimental animal models [18]. The fabricated cornea is
implanted into the eye of an experimental animal for 2 or
4 weeks, and then the cornea of the animal is extracted and
evaluated. However, hematoxylin and eosin (H&E) staining
is not suitable for evaluating a fabricated cornea during con-
tinuous research, especially in monitoring studies, thus a
noninvasive and high-resolution system should be consid-
ered for evaluating the fabricated corneas.
Optical coherence tomography (OCT) is a real-time non-
invasive, noncontact biomedical inspection technique [19], a
mainstream technology that has been widely applied in med-
ical fields, such as ophthalmology [20], dentistry [21], der-
matology [22], neurology [23, 24] and otolaryngology [25,
26]. Because OCT operates on the basis of near-infrared
light, there is no risk of invasion and radiation. Moreover,
the high-resolution imaging capability has already led to
applications involving corneal imaging for conditions, such
as keratoconus [27], corneal opacity [28], microbial keratitis
[29] and bullous keratopathy [30]. Therefore, OCT can be
applied for the monitoring of structural changes in the surgi-
cal region of the cornea.
In this study, we performed the noninvasive monitoring
of 3D bioprinted decellularized collagen sheet (3D-BDCS)-
implanted rabbit corneas in vivo using SS-OCT. The main
objective of the study was to confirm the biocompatibility of
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3D-BDCS by evaluating the corneal morphological change
in the monitored region and by a histological analysis. 3D-
BDCS was fabricated using a 3D bioprinting technique with
decellularized corneal ECM materials. The 3D-BDCS
implantation was performed on five rabbits, followed by
1 month of monitoring. As far as we are aware, this study is
the first demonstration of OCT-based in vivo monitoring of
implanted 3D-BDCS corneas.
2 | MATERIALS AND METHODS
2.1 | Fabrication of 3D-BDCS
3D-BDCSs were fabricated via a 3D cell bioprinting tech-
nique using decellularized corneal ECM containing differen-
tiated corneal stromal cells. The corneal ECM was prepared
using a decellularization process. The corneal stromal tissues
were dissected from bovine eyeballs (purchased from a
slaughterhouse in Gigye-myeon, Buk-gu, Pohang,
Gyeongsangbuk-do, South Korea) and washed with
phosphate-buffered saline (PBS) solution supplemented with
penicillin (100 U mL−1) and streptomycin (0.1 mg mL−1).
The stromal tissues were stirred in 0.5% Triton X-100
(99.9% purity, Biosesang, 697 Pangyo-ro, Bundang-gu,
Seongnam-si, Gyeonggi-do, South Korea) solution sup-
plemented with 20 mM ammonium hydroxide (NH4OH;
4.98 N, Sigma-Aldrich, St. Louis, Missouri). After being
stirred for 4 hours, the tissues were treated with hypotonic
Tris hydrochloride (Tris–HCl, pH 7.4, Biosesang) buffer
solution for 24 hours, followed by treatment with 10 mM
Tris–HCl containing 1% (v/v) Triton X-100 for the next
24 hours at 37C. Afterward, the tissues were immersed in
PBS solution for 48 hours and were then sterilized with 1%
peracetic acid (32 wt% in dilute acetic acid, Sigma-Aldrich)
solution in 50% ethanol for 10 hours. After the sterilization
process, the samples were rinsed with PBS solution and
ultrapure water. When the decellularization process was fin-
ished, the decellularized corneal ECM samples were lyophi-
lized overnight and then crushed into a fine powder using
liquid nitrogen and a milling machine. A 0.2 g quantity of
decellularized corneal ECM powder was digested in 10 mL
of 0.5 M acetic acid (Merck, Kenilworth, New Jersey) solu-
tion supplemented with 0.02 g pepsin (Sigma-Aldrich) for
3 days. After complete digestion of the decellularized cor-
neal ECM, the solution was filtered through a fine mesh with
a pore size of 100 μm and neutralized to pH 7.0–7.4 with
10 M sodium hydroxide (NaOH, Sigma-Aldrich) solution
for cell culturing.
To fabricate 3D-BDCS, the decellularized corneal ECM
hydrogel encapsulating the differentiated keratocytes [31]
was printed using a microextrusion dispensing system-
equipped (Nano master SMP-III, Musashi Engineering,
Tokyo, Japan) laboratory 3D printer using the following
parameters: feed rate = 130 mm min−1, discharge
rate = 0.0024 mm s−1, nozzle diameter = 0.29 mm and tem-
perature = 4C [32]. The differentiated keratocytes were
taken from human turbinate-derived mesenchymal stem cells
(hTMSCs) prepared in the same manner as has previously
been described in detail [28]. In brief, hTMSCs were
obtained from the Catholic University of Korea, St. Mary's
Hospital and cultured in normal Dulbecco's modified Eagle's
medium (Gibco, Gaithersburg, Maryland) containing 10%
(v/v) fetal bovine serum (Gibco) and 1% (v/v)
penicillin/streptomycin (Sigma-Aldrich) at 37C in a humid-
ified 5% CO2 atmosphere. In passage 2, normal medium was
replaced with differentiation medium containing 10 ng mL−1
keratinocyte growth factor/epidermal growth factor for 1 day
to obtain the differentiated keratocytes. The printed 3D-
BDCS, which was 5 mm in diameter and 150 μm in thick-
ness, was cross-linked in an incubator for 30 min. After-
ward, the 3D-BDCS was cultured in the differentiation
medium for 4 weeks before being implanted. The fabricated
3D-BDCS is shown in Figure 1.
2.2 | The in vivo preparation of the rabbits
The animal experiment was performed at Daegu-Gyeongbuk
Advanced Medical Innovation Foundation (DGMIF)
(80 Cheombok-ro, Dong-gu, Daegu 41 061, South Korea).
This study was approved by the Institutional Animal Care
and Use Committee of DGMIF, was performed in accor-
dance with protocol DGMIF-17080801-00 and followed the
Association for Research in Vision and Ophthalmology's
animal use guidelines. Five healthy New Zealand white rab-
bits (male, 8 weeks old, average body weight around 2 kg)
were used. 3D-BDCSs were implanted into the stromal layer
of the left corneas of two rabbits (rabbits #1 and #2) and the
right corneas of the remaining three rabbits (rabbits #3, #4
and #5). The surgery was performed under anesthesia using
FIGURE 1 Photograph of the fabricated three-dimensional
bioprinted decellularized collagen sheet
PARK ET AL. 3 of 11
a dose of ketamine (15 mg mL−1) and Rompun
(5 mg mL−1). A three-quarter-circle incision 6 mm in diame-
ter was made using a crescent knife (Alcon, Fort Worth,
TX). The 3D-BDCSs were inserted into the three-quarter-
circle incision. Three-quarter lamellar dissections were made
using a crescent knife (Alcon), then the anterior corneal flap
was lifted and the 3D-BDCS was transplanted onto the cor-
neal stromal bed. The incised site was then covered with
3D-BDCSs and sutured with 10-0 Ethilon nylon. The eyes
operated upon were treated with eye drops containing
polymyxin B, neomycin and dexamethasone (Forus, Samil
Pharmaceutical Co., Ltd., 155 Hyoryeong-ro, Seocho-gu,
Seoul, South Korea) twice a day for 2 weeks.
To undergo the experiment, the rabbits were injected
intramuscularly with a mixture of ketamine (15 mg mL−1)
and Rompun (5 mg mL−1), placed carefully on the sample
stage and kept for 10 minutes prior to the operation. To
obtain OCT images free of microdust particles, we used
physiological saline to remove foreign substances, dust par-
ticles and eyebrows. Considering the rabbits' health and the
DGMIF protocol, the experiments were performed with a
two-week interval. Four weeks after surgery, the rabbits
were euthanized.
2.3 | Configuration of the swept-source OCT
system
A schematic of the SS-OCT system (OCS1310V1, Thorlabs,
Inc., Newton, New Jersey) used in this study is shown in
Figure 2. The commercial system consists of an imaging
module, a swept-source engine with a 1310 nm wavelength
range and a bandwidth of >97 nm (−10 dB cutoff point)
and a handheld probe. The average laser output is >20 mW;
the axial scan rate and coherence length were 100 kHz and
>50 nm, respectively. The experimental transverse resolu-
tion is 25 μm, and the axial resolution is <16 μm/12 μm
(air/water). To obtain 2D OCT images, we set the field of
view (FOV) to 10 × 4.35 mm for a total pixel count of
1000 × 435. Similarly, the volumetric images were obtained
with an FOV of 10 × 10 × 4.35 mm and a pixel count of
500 × 500 × 435. The refractive index utilized was 1.38,
which was the same as used in a previous report [33]. Acqui-
sition times for 2D and 3D images were measured as 0.017
and 6 seconds, respectively. Throughout the experiment,
room temperature and humidity were maintained at 24
± 1C and 45 ± 5%, respectively.
2.4 | Depth-intensity profiling algorithm
As a depth-intensity profile analysis based on amplitude
scans (A-scans) is efficient for confirming the information
on different layers along the axial direction, we developed a
depth-intensity profile algorithm using MATLAB R2018a
(MathWorks, Inc., Natick, Massachusetts). However,
because of the nonflat physiological nature and the anatomi-
cal structure of the cornea, a flattening function was included
to rearrange each of the A-scans. Figure 3 provides a flow
chart showing the main steps of the post-processing depth-
intensity profile algorithm developed. Once the initial cross-
sectional OCT image is loaded into the program, the region
of interest (ROI) is selected to remove the speckle noise. In
this study, 50 consecutive A-scans (constant for all the
acquired images) were used as the ROI. In step 2, maximum
peak intensity points were detected (indicated by the black
FIGURE 2 A schematic of the
swept-source optical coherence
tomography (SS-OCT) system (A,
attenuator; C, collimator; CCD, charge-
coupled device; DAQ, data acquisition;
DM, dichroic mirror; Galvo,
galvanometer; L, lens; M, mirror;
MEMS, microelectromechanical
systems; OCT, optical coherence
tomography; PC, polarization
controller; VCSEL, vertical cavity
surface emitting laser)
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arrow) and rearranged to match the peak intensity index in
all of the A-scan profiles to flatten the image; this could be
confirmed through the flat corneal image in step 2. Next, all
of the A-scan profiles of the ROI were summed and divided
by the ROI range to obtain a single averaged A-scan profile.
Finally, the averaged A-scan profile was divided by the
maximum value in the averaged A-scan profile to obtain a
normalized A-scan profile. By utilizing this method, we can
confirm that unnecessary noise was removed and we could
distinguish the intensity information along the axial depth.
2.5 | The OCT image processing algorithm for
the corneal thickness measurement
Corneal thickness measurement is a major element for
assessing corneal health and condition to form a diagnosis
[34–36]. Figure 4 shows a flow chart representation of the
algorithm developed for measuring corneal thickness. Image
processing was performed to obtain a clear visualization of
distinguishable upper and lower corneal boundaries, as is
shown in the figure. As the approximate upper and lower
boundaries are difficult to distinguish, the scattering noise of
the cross-sectional OCT image was removed using the
Laplacian of Gaussian (LOG) filtering technique [37]. Sec-
ond, the grayscale image thus obtained was converted to a
binary image using Otsu's method which automatically
determines the threshold in the image [38]. Next, to facilitate
boundary detection, connected components [39] and erosion
[40] (CC & Erosion) methods were applied and repeated to
fill the empty areas in the cornea until the image no longer
changed. Last, we obtained clear upper and lower bound-
aries of the cornea using the Sobel edge detection method
[41]. To measure the corneal thickness in the obtained
FIGURE 3 A flow chart
representation of the depth-intensity
profile algorithm developed (A-scans,
amplitude scans; ROI, region of
interest)
FIGURE 4 A flow chart representation of the proposed image
processing technique for measuring the corneal thickness (CC,
connected-component; LOG, Laplacian of Gaussian)
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image, we found the shortest path between the upper and
lower boundaries of the cornea by constructing a tangent
and its perpendicular lines. We stored the pixel location at
the point where the perpendicular line intersected the upper
and lower boundaries. The distance between the two stored
values was calculated using the distance formula between
two points. The calculated value was multiplied by the pixel
resolution value of 10 μm to obtain the corneal thickness.
2.6 | Tissue preparation and histological
analysis
To evaluate the corneas through histological examination,
both eyes (oculus uterque) were extracted 4 weeks after sur-
gery. The rabbit corneas were fixed with 4% paraformalde-
hyde in PBS for 24 hours. The samples were dehydrated in a
series of ethanol solutions from 70% to 100% ethanol,
cleared with xylene and mounted in paraffin. Slides were
prepared in 6-μm-thick sections. Before being stained, the
sections were dewaxed and rehydrated. The slides were sta-
ined with H&E. The images were obtained with an Eclipse
80i microscope (Nikon, Minato, Tokyo, Japan).
3 | RESULTS AND DISCUSSION
3.1 | Morphological evaluation of the rabbit
eye samples prior to surgery
Figure 5A is a representative photograph of the rabbit eye
model used in this study. The exact scanning position used
in acquiring the cross-sectional OCT images is indicated
with a red dashed line. In Figure 5B, the outermost tear film
is observed as a high-intensity thin layer of the cornea. Simi-
larly, the low-intensity thin layer represents the epithelium.
We can also confirm the stroma which occupies most of the
FIGURE 5 (A) Photograph of a rabbit's eye used in the experiment. (B) Cross-sectional OCT image of (A) using the red dashed line as the
scanning position
FIGURE 6 Cross-sectional OCT images (A, B, C) and the corresponding depth-intensity profile analyses (D, E, F) for the control (before
surgery), and 2 and 4 weeks after surgery, respectively. The depth-intensity profile analyses correspond to the regions indicated by the red dotted
square in (A), (B) and (C), respectively. CS, 3D-BDCS. The blue, black and green arrows indicate tear film, epithelium and a layer of BDCS,
respectively
6 of 11 PARK ET AL.
cornea. A centered aiming beam of 660 nm and a visual
camera were used to more conveniently obtain the images.
3.2 | Comparison of the cross-sectional OCT
images with the depth-intensity profiles
Figure 6 shows a comparison of cross-sectional OCT images
and depth-intensity profile analyses for the control (before
surgery), and 2 and 4 weeks after surgery. The red dotted
square indicates the position analyzed in the corresponding
OCT image. The intensity shown in each graph provides a
relative representation of the quantitative value of the
scattered signal obtained from the sample. In Figure 6D-F,
the first vertex (blue arrow) represents the tear film informa-
tion. Similarly, we can see the epithelium (black arrow). The
intensity peak corresponding to the 3D-BDCS layer is
clearly distinguishable in Figure 6E,F and is indicated by a
green arrow. These results reveal that OCT is capable of
obtaining quantitative morphological evaluations as well as
performing continuous monitoring of microstructures.
3.3 | Comparison of volumetric OCT images
with orthogonal section slices
The volumetric OCT images of the rabbit corneas were
obtained by combining adjacent 2D OCT images using volu-
metric rendering software. Figure 7A-C shows close-up pho-
tographs of a rabbits' eyes using a slit-lamp microscope for
the control, and 2 and 4 weeks after surgery, respectively,
while Figure 7D-F presents volumetric 3D-rendered OCT
images with a red dotted square showing the area scanned
by combining 500 contiguous 2D OCT images. In
Figure 7B,C, we can see that the 3D-BDCS was implanted
in the eye, although the position where the 3D-BDCS had
FIGURE 7 Slit-lamp microscopic images of a rabbit's eye: (A) the control, (B) 2 weeks after surgery and (C) 4 weeks after surgery. (D),
(E) and (F) are the corresponding 3D-rendered images, and (G), (H) and (I) are the orthogonal section slice OCT images corresponding to (D),
(E) and (F), respectively. Red dotted square: area of the 3D scan
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been implanted could not be identified. Through the orthog-
onal section slice images shown in Figure 7G-I in the X-Y,
X-Z and Y-Z directions, we can confirm that the 3D-BDCS
was correctly implanted noninvasively in the middle of the
cornea (white arrow). Therefore, the OCT system could be
efficiently utilized for determining the surgical success of
the implantation of 3D-BDCS in the corneas of the rabbits.
3.4 | Evaluation of 3D-BDCS biocompatibility
with corneal thickness quantifications
We further evaluated the morphological changes in the 3D-
BDCS-implanted corneal region quantitatively to confirm
the biocompatibility of the 3D-BDCS with the rabbits' cor-
neas. The algorithm we developed (described in section 2.5)
was used for these quantifications. All of the corneal bound-
aries generated using the algorithm are highlighted in red in
Figure 8. The yellow lines in Figure 8A were used as cursors
for measuring the fluctuation in thickness between the two
boundary lines in each cross-section shown in Figure 8A-O.
The distance between the yellow cursors was approximately
150 μm. Thirty values for each 10 OCT image set in
Figure 8A-O were used to enhance the accuracy of the cor-
neal thickness measurements. The measurement values are
summarized in Table 1.
Using Figure 8 and Table 1, we analyzed and confirmed
the mean values of all the in vivo samples; the corneal thick-
ness expanded (from 430.3 to 598.5 μm) owing to effects of
the implantation surgery as well as the thickness of the 3D-
BDCS. Similarly, at 4 weeks, the mean value was calculated
as 564.5 μm. Based on these values, we determined that the
mean corneal thickness value decreased by around 5.7%
from 2 to 4 weeks. Therefore, the quantitative values
obtained show that the corneal thickness initially increased
owing to the effects of the surgery and then gradually
decreased. In other words, the corneal thickness decreased
as the edema decreased. Thus, it was assumed that the
3D-BDCS did not affect the stromal layer. Moreover, trans-
parent corneas are a prerequisite for good vision and the
endothelium has the active function of keeping the water
content of the tissue regulated. As this function decreases,
the extracellular water content of the tissue increases and
corneal thickness is increased, resulting in corneal edema
whereby light passing through the cornea is scattered and
eyesight is impaired. Therefore, central corneal thickness is
a sensitive indicator of corneal health. To evaluate the func-
tion of a bioengineered cornea as a corneal substitute, it is
necessary to examine its thickness and morphology through
in vivo experiments. Inspection methods that can simulta-
neously evaluate thickness along with the morphological sta-
tus of the cornea have been scarce. Thus, we performed
noninvasive monitoring of bioengineered cornea in rabbit
corneas in vivo using swept-source OCT (SS-OCT), where
the main objective of the study was to confirm the biocom-
patibility by evaluating the corneal thickness and morpho-
logical change in the monitored region.
The bioengineered corneal substitutes used in this experi-
ment were fabricated using a bioprinting technique followed
by a crosslinking procedure. Although crosslinking was used
to make the constructs hard, this was not mechanically suffi-
cient to resist the pressure inside the pocket, so we expected
them to become half of their original thickness after trans-
plantation. Nevertheless, we obtained better results than we
expected and they tolerated biodegradation well.
FIGURE 8 2D OCT images of samples with detected corneal boundaries (marked as a red line) for the control (A, D, G, J, M), 2 weeks after
surgery (B, E, H, K, N), and 4 weeks after surgery (C, F, I, L, O) for rabbits #1-#5, respectively. Scale bar: 500 μm
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We performed H&E staining to evaluate the biocompatibil-
ity of 3D-BDCS. Figure 9 shows images of the H&E staining
conducted to evaluate the immune response. Because there was
no preoperative histology for the same eye, the opposite eye
without the 3D-BDCS implant was evaluated as a control.
Figure 9A shows H&E staining of the opposite cornea and
Figure 9C shows that for implanted one. Figure 9B,D are
enlargements of the areas in the red dotted squares shown in
Figure 9A,C, respectively. No inflammatory cells were found in
Figure 9B. In Figure 9D, inflammatory cells (red-dashed circles)
were occasionally observed in the vicinity of the 3D-BDCS.
Nevertheless, T lymphocytes, which play a crucial role in cell-
mediated immunity [18, 42], were not observed.
After transplantation, the epithelium around the incised
area was destroyed, but within a few days, the entire ocular
surface had stabilized. The altered epithelium seems to have
been broken during the histologic processing. In general,
infiltrated inflammatory cells can be distinguished by H&E,
which is also the case for the cornea [43]. As shown in
Figure 9, the inflammatory cells are more intensely stained
with hematoxylin than the stroma, endothelial, and epithelial
cells and also have a very small distribution of cytoplasm. In
addition to this, the round shape of the nucleus is also indic-
ative of inflammatory cells and makes them distinct from
stromal cells. There are a number of different types of
inflammatory cells (eg, granulocytes [basophils, neutrophils,
TABLE 1 Corneal thickness statistics
for rabbits #1 to #5
#1 #2 #3 #4 #5 Total average
Control
Mean 426.7 434.2 427.4 424.9 438.5 430.3
SD 5.9 9.2 6.1 3.4 4.7 5.9
Min. 418.9 421.3 418.7 420.7 430.1 421.9
Max. 437.0 450.6 435.0 429.1 445.4 439.4
2 weeks
Mean 560.1 641.4 605.2 632.6 553.4 598.5
SD 10.7 28.3 7.5 4.3 8.0 11.8
Min. 541.6 600.3 592.0 627.4 538.4 579.9
Max. 571.3 677.1 613.7 639.0 562.0 612.6
4 weeks
Mean 524.1 580.8 597.0 592.7 527.8 564.5
SD 7.4 28.9 8.5 9.1 8.8 12.5
Min. 512.6 542.7 588.0 577.2 511.8 546.5
Max. 533.4 623.3 610.0 606.0 540.9 582.7
Note: Units in μm.
Abbreviations: Max., maximum value; Min., minimum value; SD, standard deviation.
FIGURE 9 Representative
images of hematoxylin and eosin
(H&E) staining showing the histology
of the rabbit corneas: (A) the control
(the cornea without 3D-BDCS
implantation) and (C) 4 weeks after
surgery. (B) and (D) are enlargements
of the areas in the red dotted squares
shown in (A) and (C), respectively.
CS: 3D-BDCS, Red dotted circle:
inflammatory cell
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and eosinophils], macrophages, monocytes and T cells). As
shown, there were very few macrophages and monocytes,
and T cells identified by a dark stained small dot were not
observed. Hence, it is evident that some inflammatory cell
types (including T cells) were not present and the remaining
ones were sufficiently classified by H&E, thus we consid-
ered that an immunostaining method was unnecessary.
Indeed, we have already carried out an analysis of inflamma-
tory cells [44–46]. Consequently, after considering all of the
H&E stained images, we can confirm that the 3D-BDCS
associated well with the stromal layer. Our results suggest
that there was no serious immunorejection response when
3D-BDCS was implanted into the cornea of rabbits, and we
can confirm the biocompatibility of 3D-BDCS by the
changes in corneal thickness and the distribution of inflam-
matory cells. Based on these data, it is expected that 3D-
BDCS can be a promising material for corneal implants.
In ophthalmological point of view, the biocompatibility
of the transplanted 3D-BDCS can be confirmed through the
overall thickness reduction of corneal layer after few weeks
of the surgery, which can only be verified precisely via dis-
sections. According to the acquired OCT results during
biweekly monitoring process, mean corneal thickness value
at 4 weeks decreased by around 5.7% compared with the
measurements at 2 weeks, which reveals a clear correlation
with the examined histological analysis. These results indi-
cate that corneal edema caused by the surgical operation
decreased over time, indicating the reduction of foreign body
reaction, which showed a similar tendency to that in a previ-
ously published article [47]. In addition, the histological
results with few inflammatory cells clearly support this
supposition.
4 | CONCLUSIONS
We performed the monitoring of 3D-BDCS-implanted rabbit
corneas in vivo for 1 month using a swept-source OCT tech-
nique at a wavelength of 1310 nm. Based on the high resolu-
tion of OCT, we were able to assess the minute
morphological changes in rabbit corneas in which 3D-BDCS
had been implanted. Variations in cornea thickness were
quantitatively measured in vivo through image processing
based on depth-intensity profiling during the monitoring. To
further confirm the biocompatibility of the 3D-BDCS with
corneal specimens, a histological analysis was performed by
extracting the rabbits' eyes post mortem and staining the tis-
sues with H&E. Through the results of our investigation of
the changes in corneal thickness and the distributions of
inflammatory cells, we confirmed the biocompatibility of the
fabricated 3D-BDCS. Although OCT-based anterior seg-
ment imaging has been performed numerous times, the con-
ceptual breakthrough of the study was the development of
3D-BDCS and non-invasive biocompatibility confirmation
of transplanted cornea through a bi-weekly monitoring pro-
cess using SS-OCT in vivo. As the cross-sections and enface
visualizations were acquired with sufficient resolution and
depth visibility, currently existing SS-OCT engine-based
imaging techniques were used to conduct the study.
As a future study, evaluations of corneal transparency
and stiffness could be conducted to confirm that 3D-BDCS
can be used in artificial corneas. Moreover, ultrahigh-
resolution optical coherence microscopy for evaluation such
as measuring the 3D-BDCS thickness is expected to provide
a better research environment for researchers in various bio-
medical and tissue engineering areas.
AUTHOR BIOGRAPHIES




[1] B. D. Ayres, C. J. Rapuano, Compr. Ophthalmol. Updat. 2006, 7,
243 discussion 253-245.
[2] F. E. Kruse, C. Cursiefen, Dev. Ophthalmol. 2008, 41, 159.
[3] K. McColgan, J. Perioper. Pract. 2009, 19, 51.
[4] G. R. Melles, L. Remeijer, A. J. Geerards, W. H. Beekhuis, Curr.
Opin. Ophthalmol. 1999, 10, 253.
[5] K. Nishida, Cornea 2003, 22, S28.
[6] J. P. Garcia Jr.. , D. C. Ritterband, D. F. Buxton, J. De la Cruz,
Cornea 2010, 29, 1031.
[7] B. L. Shapiro, D. E. Cortés, E. K. Chin, J. Y. Li, J. S. Werner,
E. Redenbo, M. J. Mannis, Cornea 2013, 32, 951.
[8] W. B. Lee, R. M. Shtein, S. C. Kaufman, S. X. Deng,
M. I. Rosenblatt, Ophthalmology 2015, 122, 1504.
[9] S. Zarei-Ghanavati, C. Betancurt, A. M. Mas, J. Wang,
V. L. Perez, J. Ophthalmic Vis. Res. 2015, 10, 26.
[10] S. Siebelmann, P. Steven, D. Hos, G. Hüttmann, E. Lankenau,
B. Bachmann, C. Cursiefen, J. Biomed. Opt. 2016, 21, 016005.
[11] T. L. Lenis, S. Y. Chiu, S. K. Law, F. Yu, A. J. Aldave, Ophthal-
mology 2017, 124, 12.
[12] S. B. Seif-Naraghi, M. A. Salvatore, P. J. Schup-Magoffin,
D. P. Hu, K. L. Christman, Tissue Eng. A 2010, 16, 2017.
[13] J. A. DeQuach, J. E. Lin, C. Cam, D. Hu, M. A. Salvatore,
F. Sheikh, K. L. Christman, Eur. Cell. Mater. 2012, 23, 400.
[14] H. Engel, S.-W. Kao, J. Larson, S. Uriel, B. Jiang, E. Brey, M.-
H. Cheng, Biom. J. 2015, 38, 58.
[15] R. A. Pouliot, P. A. Link, N. S. Mikhaiel, M. B. Schneck,
M. S. Valentine, F. J. Kamga Gninzeko, J. A. Herbert,
M. Sakagami, R. L. Heise, J. Biomed. Mater. Res. A 2016, 104,
1922.
[16] A. E. Loneker, D. M. Faulk, G. S. Hussey, A. D'Amore,
S. F. Badylak, J. Biomed. Mater. Res. A 2016, 104, 957.
10 of 11 PARK ET AL.
[17] J. Jang, J. Y. Park, G. Gao, D.-W. Cho, Biomaterials 2018,
156, 88.
[18] E. Koudouna, N. Okumura, Y. Okazaki, S. Nakano, R. Inoue,
N. J. Fullwood, J. Hori, S. Kinoshita, N. Koizumi, Invest.
Ophthalmol. Vis. Sci. 2017, 58, 242.
[19] D. Huang, E. A. Swanson, C. P. Lin, J. S. Schuman,
W. G. Stinson, W. Chang, M. R. Hee, T. Flotte, K. Gregory,
C. A. Puliafito, Science 1991, 254, 1178.
[20] Y. Jia, S. T. Bailey, D. J. Wilson, O. Tan, M. L. Klein,
C. J. Flaxel, B. Potsaid, J. J. Liu, C. D. Lu, M. F. Kraus, Ophthal-
mology 2014, 121, 1435.
[21] R. E. Wijesinghe, N. H. Cho, K. Park, M. Jeon, J. Kim, Sensors
2016, 16, 2076.
[22] S. A. Alawi, M. Kuck, C. Wahrlich, S. Batz, G. McKenzie,
J. W. Fluhr, J. Lademann, M. Ulrich, Exp. Dermatol. 2013,
22, 547.
[23] F. Costello, S. Coupland, W. Hodge, G. R. Lorello, J. Koroluk,
Y. I. Pan, M. S. Freedman, D. H. Zackon, R. H. Kardon, Ann.
Neurol. 2006, 59, 963.
[24] D. Choi, J. Lee, M. Jeon, J. Kim, IEEE Access. 2018, 6, 7713.
[25] J. Lee, R. E. Wijesinghe, D. Jeon, P. Kim, Y.-H. Choung,
J. H. Jang, M. Jeon, J. Kim, Sci. Rep. 2018, 8, 17432.
[26] N. H. Cho, J. H. Jang, W. Jung, J. Kim, Opt. Express 2014, 22,
8985.
[27] Y. Li, D. M. Meisler, M. Tang, A. T. Lu, V. Thakrar, B. J. Reiser,
D. Huang, Ophthalmology 2008, 115, 2159.
[28] R. N. Khurana, Y. Li, M. Tang, M. M. Lai, D. Huang, Ophthal-
mology 2007, 114, 1278.
[29] A. Konstantopoulos, J. Kuo, D. Anderson, P. Hossain, Am.
J. Ophthalmol. 2008, 146, 534.
[30] C. Wirbelauer, J. Winkler, G. O. Bastian, H. Häberle, D. Pham,
Graefe's Arch. Clin. Exp. Ophthalmol. 2002, 240, 727.
[31] M. Park, B. Kim, H. Kim, S. Hwa Park, M. Hyun Lim, Y. j. Choi,
H. G. Yi, J. Jang, S. Kim, D. W. Cho, J. Clin. Exp. Ophthalmol.
2017, 8, 627.
[32] H. Kim, J. Jang, J. Park, K. Lee, S. Lee, D. Lee, K. H. Kim,
H. K. Kim, D. Cho, Biofabrication 2019, 11, 035017.
[33] S. Patel, J. Marshall, F. W. Fitzke, J. Refract. Surg. 1995,
11, 100.
[34] D. S. Grewal, G. S. Brar, S. P. Grewal, J. Cataract Refract. Surg.
2010, 36, 954.
[35] E. N. Vithana, T. Aung, C. C. Khor, B. K. Cornes, W.-T. Tay,
X. Sim, R. Lavanya, R. Wu, Y. Zheng, M. L. Hibberd, Hum. Mol.
Genet. 2010, 20, 649.
[36] R.-P. Copt, R. Thomas, A. Mermoud, Arch. Ophthalmol. 1999,
117, 14.
[37] H. Kong, H. C. Akakin, S. E. Sarma, IEEE Trans. Cybernet.
2013, 43, 1719.
[38] N. Otsu, IEEE Trans. Syst. Man Cybern. 1979, 9, 62.
[39] K. Suzuki, I. Horiba, N. Sugie, Comput. Vis. Image Underst.
2003, 89, 1.
[40] P. Vogt, K. H. Riitters, C. Estreguil, J. Kozak, T. G. Wade,
J. D. Wickham, Landsc. Ecol. 2007, 22, 171.
[41] R. Maini, H. Aggarwal, Int. J. Image Process. 2009, 3, 1.
[42] J. Y. Niederkorn, Int. Rev. Immunol. 2013, 32, 57.
[43] Z. Jia, F. Li, X. Zeng, Y. Lv, S. Zhao, BMC Ophthalmol. 2018,
18, 139.
[44] S. Kang, K. P. Lee, S. J. Park, D. Y. Noh, J. M. Kim,
H. R. Moon, Y. G. Lee, Y. W. Choi, D. S. Im,
J. Ethnopharmacol. 2014, 153, 242.
[45] K. P. Lee, S. Kang, M. S. Noh, S. J. Park, J. M. Kim,
H. Y. Chung, N. K. Je, Y. G. Lee, Y. W. Choi, D. S. Im, Biomol.
Ther. 2015, 23, 45.
[46] K. P. Lee, S. Kang, S. J. Park, J. M. Kim, J. M. Lee, A. Y. Lee,
H. Y. Chung, Y. W. Choi, Y. G. Lee, D. S. Im,
J. Ethnopharmacol. 2015, 173, 361.
[47] J. Andersen, N. Ehlers, Acta Ophthalmol. 1986, 64, 93.
How to cite this article: Park J, Lee K-P, Kim H,
et al. Biocompatibility evaluation of bioprinted
decellularized collagen sheet implanted in vivo cornea
using swept-source optical coherence tomography. J.
Biophotonics. 2019;12:e201900098. https://doi.org/
10.1002/jbio.201900098
PARK ET AL. 11 of 11
